Economy

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Stifel Nicolaus

The institutional investor owned 1,221,338 shares of the biopharmaceutical company's stock after selling 20,000 shares during the quarter.

Heading into the stock price potential, EdR needs to grow just 7.47% to cross its median price target of $41.

In the most updated research from a number of analysts on Wall Street, the company gets 11 Buys and 1 Sell among 18 analysts.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 112.92 on Wednesday.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s earnings per share has been growing at a -28.7 percent rate over the past 5 year when average revenue increase was noted as -10.6 percent. Finally, Chardan Capital reiterated a "buy" rating and set a $131.00 target price (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an equal weight rating in a research report on Thursday, August 10th. BidaskClub lowered Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, August 16th. (NASDAQ:ALNY). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The consensus analyst target price is $88.63.

Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 3.450% during trading on Friday, hitting $116.816.

At the time of writing, the stock was trading at $1.69. Alnylam Pharmaceuticals, Inc. The firm has a 50-day moving average of $81.14 and a 200-day moving average of $69.12. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $118.40. The company has market cap of $10.54 billion. Alnylam Pharmaceuticals also was the target of some unusual options trading on Wednesday. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. This represents an increase of 937% compared to the average volume of 2,944 call options. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. September 21 investment analysts at Leerink Swann kept the company rating at "Outperform" but raised the price expectation from $50.00 to $123.00. During the same period in the previous year, the business posted ($1.05) EPS. The company's revenue for the quarter was up 82.9% on a year-over-year basis. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of USA and worldwide trademark & copyright legislation. FMR LLC grew its stake in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter.

Investors are feeling more bullish on shares of the company of late if you watch the decrease in short interest. Wellington Management Group LLP grew its stake in Alnylam Pharmaceuticals by 0.3% in the 1st quarter. The Manufacturers Life Insurance Company increased its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company's stock valued at $203,000 after buying an additional 167 shares during the last quarter. BlackRock Inc. grew its stake in Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Manufacturers Life Ins The owns 2,541 shares or 0% of their U.S. portfolio. Finally, Baillie Gifford & Co. grew its stake in Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. The short sellers then promise to replace the stock in the future and makes dividend payments out of their own pockets to cover the dividend income that is no longer exists on the original, now borrowed and sold, shares. The percentage of shares being held by the company management was 0.7% while institutional stake was 89.9%.



Like this

loading...
loading...

Latest


23 September 2017
DG Punjab Rangers visits Harpal, Charwa sectors
A day before, Indian troops resorted to shelling, targeting civilian population on the Pakistan side of the Working Boundary. Despite calls for restraint, India continues to indulge in ceasefire violations.

23 September 2017
Boston Scientific Corp (NYSE:BSX) Institutional Investors Sentiment
Over the last five days, shares have faced -0.72% losses and now is up 12.3% since hitting its 200-day moving average of $26.61. The institutional investors in our partner's database now hold: 1.22 billion shares, down from 1.23 billion shares in 2017Q1.

23 September 2017
Boy, 17, arrested in connection with Parsons Green tube attack
A man in a red hat - carrying a Lidl bag - was also captured by cameras near the Jones's home about 90 minutes before the attack. A suicide bomber attacked a concert venue in Manchester in May, killing more than 20 people including children and mothers.

23 September 2017
Hostages released by man armed with machete at Tennessee bank
A heavily armed SWAT unit has surrounded a United States bank where a man armed with a machete has reportedly taken hostages. Three of the hostages were eventually released, but six people remain trapped inside the Community First Bank and Trust.

23 September 2017
Lawmakers to grill Equifax, Wells CEOs in busy week of hearings
The bank paid a $185 million settlement last year with multiple authorities, then added another $142 million earlier this year to settle a class-action suit.

23 September 2017
Exelon Corporation (NYSE:EXC) EVP Sells $510787.23 in Stock
The Company, through its subsidiary, Exelon Generation Company, LLC (Generation), is involved in the energy generation business. Also, EVP Paymon Aliabadi sold 13,333 shares of the stock in a transaction that occurred on Monday, September 11th.

23 September 2017
5 things to know about N. Korean leader's rebuke of Trump
The North Korean leader earlier labelled Trump "mentally deranged" and a "dotard" after Trump threatened to destroy his country. But the speech was textbook Trump , dividing the globe into friends and foes and taking unflinching aim at America's enemies.

23 September 2017
South Park: The Fractured But Whole trailer mocks Kanye's 'Only One' videogame
Now, that mockery has become reality as part of a new trailer for their own game South Park: The Fractured But Whole . The new trailer follows the New Kid as he teams up with Seaman to help a gay fish help his mom get into Heaven.

23 September 2017
Records third victory with win over Boise State 42-23
Senior quarterback Kurt Benkert , for his part, had a school-record performance, throwing for 455 yards and three TDs in the rout. Virginia's defense held Boise State to just 30 yards rushing, while the Cavaliers' offense rolled up 167 yards on the ground.

23 September 2017
Stock Showing Surging Activity: Newell Brands Inc. (NWL)
The stock has "Buy" rating by UBS on Wednesday, August 12. 1832 Asset Mngmt Limited Partnership stated it has 379 shares. The consensus recommendation, according to Zacks Investment research , is 1.54. (NYSE:NWL) has gone weaker by -20.99%.